 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- budoprutug (TNT119) / Eliem Therap
Trial completion date, Trial termination: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Apr 22, 2024
P2, N=1, Terminated, Sponsor: Tenet Medicines
Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sponsor change
- | budoprutug (TNT119) / Eliem Therap
Enrollment closed, Phase classification, Enrollment change, Trial completion date: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=6, Active, not recruiting, Sponsor: Tenet Medicines
Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sponsor change Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | N=30 --> 6 | Trial completion date: Oct 2023 --> Aug 2024
- | budoprutug (TNT119) / Eliem Therap
Enrollment change, Trial completion date: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Feb 15, 2024
P2, N=1, Active, not recruiting, Sponsor: Tenet Medicines
Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | N=30 --> 6 | Trial completion date: Oct 2023 --> Aug 2024 N=20 --> 1 | Trial completion date: Nov 2023 --> Aug 2024
- | budoprutug (TNT119) / Eliem Therap
Enrollment closed, Trial completion date, Trial primary completion date: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Jan 13, 2023
P2, N=20, Active, not recruiting, Sponsor: ValenzaBio, Inc.
N=20 --> 1 | Trial completion date: Nov 2023 --> Aug 2024 Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Nov 2023 --> Jun 2023
- VB119 / ValenzaBio
A Phase 1b/2a Single Arm Open-Label Study of VB119, an Anti-CD 19 Monoclonal Antibody (Mab), in Active Primary Membranous Nephropathy (PMN): An Interim Report (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3849;
All participants receiving VB119 and having observations ≥6 weeks through September 15, 2022 will be reported. Proteinuria, PLA2R and Total B-cell change over time
- || budoprutug (TNT119) / Eliem Therap
New P2 trial: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Jul 1, 2022
P2, N=20, Recruiting, Sponsor: ValenzaBio, Inc.
- || budoprutug (TNT119) / Eliem Therap
Enrollment open: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy (clinicaltrials.gov) - May 12, 2021
P1b/2a, N=30, Recruiting, Sponsor: ValenzaBio, Inc.
Proteinuria, PLA2R and Total B-cell change over time Not yet recruiting --> Recruiting